U.S. markets open in 3 hours 55 minutes
  • S&P Futures

    3,688.50
    -20.50 (-0.55%)
     
  • Dow Futures

    29,505.00
    -164.00 (-0.55%)
     
  • Nasdaq Futures

    11,335.00
    -41.75 (-0.37%)
     
  • Russell 2000 Futures

    1,674.10
    -12.00 (-0.71%)
     
  • Crude Oil

    78.14
    -0.60 (-0.76%)
     
  • Gold

    1,652.40
    -3.20 (-0.19%)
     
  • Silver

    18.65
    -0.26 (-1.37%)
     
  • EUR/USD

    0.9680
    -0.0008 (-0.09%)
     
  • 10-Yr Bond

    3.6970
    0.0000 (0.00%)
     
  • Vix

    32.05
    +4.70 (+17.18%)
     
  • GBP/USD

    1.0727
    -0.0130 (-1.20%)
     
  • USD/JPY

    143.9260
    +0.6060 (+0.42%)
     
  • BTC-USD

    19,183.53
    +105.76 (+0.55%)
     
  • CMC Crypto 200

    439.26
    -5.28 (-1.19%)
     
  • FTSE 100

    7,005.66
    -12.94 (-0.18%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 89% Above Its Share Price

·6 min read

How far off is Sotera Health Company (NASDAQ:SHC) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. This will be done using the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

Check out our latest analysis for Sotera Health

Crunching The Numbers

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) forecast

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

Levered FCF ($, Millions)

US$306.6m

US$373.0m

US$422.0m

US$463.3m

US$497.7m

US$526.4m

US$550.8m

US$571.8m

US$590.5m

US$607.4m

Growth Rate Estimate Source

Analyst x2

Analyst x1

Est @ 13.14%

Est @ 9.78%

Est @ 7.43%

Est @ 5.78%

Est @ 4.63%

Est @ 3.82%

Est @ 3.26%

Est @ 2.86%

Present Value ($, Millions) Discounted @ 6.5%

US$288

US$329

US$350

US$360

US$364

US$361

US$355

US$346

US$336

US$324

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$3.4b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.5%.

Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = US$607m× (1 + 1.9%) ÷ (6.5%– 1.9%) = US$14b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$14b÷ ( 1 + 6.5%)10= US$7.3b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$11b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of US$20.0, the company appears quite good value at a 47% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

The Assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Sotera Health as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.5%, which is based on a levered beta of 1.071. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For Sotera Health, we've put together three important aspects you should explore:

  1. Risks: You should be aware of the 2 warning signs for Sotera Health (1 makes us a bit uncomfortable!) we've uncovered before considering an investment in the company.

  2. Future Earnings: How does SHC's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here